INTRODUCTION
============

Pediatric-onset IBD is increasing in many countries \[[@b1-ir-2018-00128],[@b2-ir-2018-00128]\]. It accounts for 15% to 25% of IBD cases, and 4% to 10% of pediatric-onset IBD cases are diagnosed in children under the age of 6 \[[@b3-ir-2018-00128]\]. The annual incidence of pediatric-onset IBD has been reported to be as high as 23, 15.2, and 11.4 per 100,000 personyears in Europe, North America, and Asia, respectively \[[@b4-ir-2018-00128]\].

In contrast to adult-onset IBD, pediatric-onset IBD often shows extensive disease and rapid progression requiring early immunomodulatory therapy \[[@b5-ir-2018-00128],[@b6-ir-2018-00128]\]. Furthermore, medical treatment as well as IBD itself can affect many aspects such as growth, education, employment, psychosocial and sexual development in pediatric patients \[[@b7-ir-2018-00128]\]. Since IBD is a lifelong disorder and disease-related morbidity can be high, a smooth and successful transition from pediatric to adult care is important.

However, several barriers have been reported that interfere with successful transition. Patients with IBD often show inadequacies in their preparation for transition, such as a lack of knowledge about the condition and its treatment and a lack of self-management skills \[[@b8-ir-2018-00128],[@b9-ir-2018-00128]\]. In a Western study, 65% of adult gastroenterologists reported that training in adolescent care was suboptimal \[[@b9-ir-2018-00128]\]. Only half of pediatric gastroenterologists reported that they are familiar with the published transition guidelines, and only 12% reported that their approach to transition was mostly or entirely based on the guidelines \[[@b10-ir-2018-00128]-[@b12-ir-2018-00128]\]. In addition, most institutions did not have a written transition policy and lacked the resources and training for transition care \[[@b13-ir-2018-00128]\]. There was also a perception gap between pediatric and adult gastroenterologists regarding transition management and patients' competencies for successful transition \[[@b9-ir-2018-00128]\].

Several previous reviews about transition care in IBD have extensively focused on the topics such as pediatric and adult IBD care paradigms, concepts of transition, current practice of transition care, skills needed for successful transition, evaluation of transition readiness, structured transition care program and process, barriers and outcomes of transition, and transition recommendations \[[@b14-ir-2018-00128]-[@b18-ir-2018-00128]\]. In this review, we will summarize the key practical knowledge for successful transition from current literatures and actions required by pediatric and adult gastroenterologists who are preparing for transition care.

EPIDEMOLOGY AND CLINICAL CHARACTERISTICS OF PEDIATRIC-ONSET AND ADULT-ONSET IBD
===============================================================================

In previous studies, the age for classifying pediatric-onset and adult-onset IBD ranged from 15 to 19 years \[[@b19-ir-2018-00128]\]. Pediatric IBD differs from adult IBD in several clinical aspects. In Western literatures, CD was reported to be 1.6 to 3.1 times more common than UC in pediatric-onset IBD patients, whereas CD was 0.85 times less common than UC in adult-onset IBD patients \[[@b6-ir-2018-00128],[@b20-ir-2018-00128]-[@b22-ir-2018-00128]\]. In a Japanese nationwide registry, UC to CD ratio in children was 2.7, which was lower than the figure in adults (5.1) \[[@b23-ir-2018-00128]\]. Although there are some differences in the incidence rates for overall IBD, the incidence of UC is slightly higher among men, while the incidence of CD is 20% to 30% higher among women in high-incidence areas, and CD occurs more frequently among men in some low-incidence areas \[[@b24-ir-2018-00128]\]. In pediatric-onset IBD groups, there is a male predominance for CD and no gender predilection for UC \[[@b23-ir-2018-00128],[@b25-ir-2018-00128],[@b26-ir-2018-00128]\]. Regarding familial clustering, 21% of pediatric-onset IBD patients had affected first- or second-degree relatives in a population-based study from Wisconsin \[[@b27-ir-2018-00128]\]. A family history of IBD has been also reported to be more frequent in pediatric-onset than adult-onset IBD patients according to a population-based study from northern France and a nationwide registry from Japan \[[@b23-ir-2018-00128],[@b28-ir-2018-00128]\].

In pediatric-onset CD patients on the EUROKIDS registry, the ileocolon (L3, 53%) was the most frequently involved site at diagnosis, followed by the colon (L2, 27%), isolated terminal ileal disease with or without limited cecal disease (L1, 16%), and isolated upper (GI) tract (L4, 4%) \[[@b29-ir-2018-00128]\]. Upper GI tract involvement (L4) was reported in 54% of pediatric CD cases \[[@b29-ir-2018-00128]\]. Compared to adult-onset CD, pediatric-onset CD has a higher proportion of panenteric/extensive disease (L3+L4: 43% vs. 3%, *P*\<0.001) and less frequent isolated ileal (L1: 3% vs. 32%, *P*\<0.001) and colonic disease (L2: 15% vs. 36%, *P*\<0.001) at diagnosis in a Scottish patient population \[[@b6-ir-2018-00128]\]. With regard to the behavior of CD, most patients (82%) had inflammatory disease (B1), and 12% and 5% had structuring (B2) and penetrating disease (B3) at diagnosis, respectively \[[@b29-ir-2018-00128]\]. Perianal disease (p) was reported in 9% of pediatric-onset CD patients \[[@b29-ir-2018-00128]\]. In pediatric-onset UC patients on the EUROKIDS registry, pancolitis (E4), extensive colitis (E3), left-sided colitis (E2), and proctitis (E1) were reported in 69%, 9%, 18%, and 5% of patients at diagnosis, respectively \[[@b30-ir-2018-00128]\]. Similarly, according to Asian studies, at diagnosis, ileocolonic involvement (L3) and inflammatory disease (B1) were the most common phenotype in pediatric-onset CD, and extensive colitis (E3) was also the most common disease extent in pediatric-onset UC \[[@b23-ir-2018-00128],[@b31-ir-2018-00128]-[@b33-ir-2018-00128]\].

In a French cohort study, active disease, defined as the occurrence of a flare-up or a complication during each year between 1995 and 2007, was more frequently observed in pediatric-onset than adult-onset CD patients (37% vs. 31% of patient-years, *P*\<0.001) between 1995 and 2007 (A total of 6,585 patient-years evaluated) \[[@b34-ir-2018-00128]\]. Progression to stricturing or penetrating phenotypes (B2 or B3) from inflammatory behavior (B1) was reported in 24% to 43% and 14% to 44% of pediatriconset CD patients, respectively \[[@b35-ir-2018-00128]\]. New perianal complications developed in 10% to 20% of patients between 5 and 10 years after the diagnosis of CD \[[@b19-ir-2018-00128]\]. In pediatric-onset UC patients, proximal disease extension was observed in half of the patients, and extensive colitis was observed in two-thirds of the patients at the end of various follow-up periods \[[@b36-ir-2018-00128]\].

Approximately 20% of pediatric-onset CD patients first present with short stature, predominant perianal disease, anemia, or other extraintestinal manifestations \[[@b37-ir-2018-00128]\]. Overall, a large proportion of CD patients (65%--75%) have been reported to be undernourished \[[@b38-ir-2018-00128]\]. Undernutrition, particularly in pediatriconset CD patients, is associated with stunting, linear growth retardation, and delayed puberty \[[@b39-ir-2018-00128]\]. The etiology of growth failure is multifactorial and includes chronic undernutrition, increased metabolic demand, cytokine-induced growth hormone resistance, and corticosteroids \[[@b40-ir-2018-00128]\]. Impairment of linear growth may be observed in up to 46% and 3% to 10% of pediatric-onset CD and UC patients at the time of diagnosis, respectively \[[@b41-ir-2018-00128]\]. According to a population-based study from France and a cohort study from the United States, 29% and 11.3% of pediatric-onset CD patients did not reach their target height, respectively \[[@b42-ir-2018-00128],[@b43-ir-2018-00128]\]. Since the largest increases in bone mass occurs between the ages of 12 to 15 years in girls and 14 to 17 years in boys, adequate bone mass may not be achieved, and the risk of fracture could increase in pediatric-onset IBD patients \[[@b35-ir-2018-00128],[@b44-ir-2018-00128]\]. Furthermore, a significant proportion of pediatriconset CD patients suffer from growth retardation and undernutrition during the course of the disease \[[@b19-ir-2018-00128]\]. In contrast, pediatric-onset UC patients may not show significant growth retardation after the initiation of medical therapy \[[@b45-ir-2018-00128]\]. With regard to pubertal maturity, pediatric-onset IBD patients showed a tendency toward delayed puberty \[[@b46-ir-2018-00128],[@b47-ir-2018-00128]\]. The median ages of menarche of girls with IBD and the general population were 14.6 and 13.1 years, respectively \[[@b47-ir-2018-00128]\]. The age of onset of puberty (testicular volume \> 4 mL) in boys with IBD and in the general population was 13.9 and 12.9 years, respectively \[[@b47-ir-2018-00128]\].

In summary, there is a difference in epidemiology and clinical characteristics between pediatric-onset and adult-onset IBD. Pediatric-onset IBD patients usually show more extensive bowel involvement and worse disease course compared to adult-onset IBD patients. Growth and pubertal maturity are significant issues in pediatric-onset IBD.

DIAGNOSTIC TESTS AND TREATMENTS OF PEDIATRIC-ONSET AND ADULT-ONSET IBD
======================================================================

Radiologic imaging modalities such as CT scans and MRI in the diagnosis and management of CD showed similar sensitivity and specificity for both pediatric-onset and adult-onset IBD patients \[[@b48-ir-2018-00128]\]. However, when performing radiologic imaging tests especially in pediatric patients, care providers should consider not only the diagnostic accuracy of the tests, but also the minimization of ionizing radiation exposures from CT and barium studies, the possibility of taking oral contrast agents, and the tolerability for a long time inside magnetic resonance scanncer \[[@b48-ir-2018-00128],[@b49-ir-2018-00128]\]. Furthermore, since suboptimal bowel preparation can occur in up to one-third of colonoscopies in pediatric patients, ideal preparation protocol to achieve optimal bowel preparation should be considered \[[@b50-ir-2018-00128]\]. Due to difficulties in performing radiologic and endoscopic evaluation in pediatric IBD patients, non-invasive diagnostic and monitoring tools such as fecal calprotectin could be more useful in pediatric patients.

Since exclusive enteral nutrition has an excellent safety profile and similar efficacy compared with corticosteroids in inducing remission, it is recommenced as a steroid-sparing treatment for the induction of remission in pediatric-onset CD patients with active luminal disease \[[@b51-ir-2018-00128]\]. In recent studies, 12% to 37% of pediatric-onset CD patients were reported to be corticosteroid-dependent, which is similar to the proportion of corticosteroid-dependent pediatric-onset UC patients (10%--50%) \[[@b19-ir-2018-00128],[@b36-ir-2018-00128]\]. The cumulative rates of requiring corticosteroids (96% vs. 91%, *P*=0.03), thiopurine (72% vs. 61%, *P*\<0.01), methotrexate (19% vs. 10%, *P*\<0.01), and anti-TNF agent (26% vs. 13%, *P*\<0.001) were significantly higher in pediatric-onset CD than in adult-onset CD according to a matched comparison study conducted in France \[[@b34-ir-2018-00128]\]. The use of immunomodulators has significantly increased over time, and this has been associated with a reduction in surgical risk in pediatric-onset CD patients \[[@b21-ir-2018-00128],[@b52-ir-2018-00128]\]. The rates of primary and long-term response to infliximab in pediatric-onset CD patients were reported as 75% to 97% and 54% to 83%, respectively \[[@b19-ir-2018-00128]\]. The efficacy and safety profiles of infliximab seems to be similar to those of adult-onset CD patients \[[@b53-ir-2018-00128]\]. Although there were no significant differences in the cumulative risk of surgery, the risk of having an extensive intestinal resection (48%±5% vs. 14%±2%, *P*\<0.001) and permanent stoma (12%±3% vs. 1% ± 0.5%, *P*\<0.001) were significantly higher in pediatric-onset CD than in adult-onset CD patients till the age of 30 years \[[@b34-ir-2018-00128]\].

Pediatric-onset UC patients often have extensive disease with aggressive phenotypes, and escalation to immunomodulators and anti-TNF agents is therefore indicated more frequently compared with adult-onset UC patients \[[@b54-ir-2018-00128]\]. In a populationbased cohort study from Copenhagen County and City, systemic corticosteroids and immunomodulators were more commonly used, and corticosteroid-dependency was more frequently observed in pediatric-onset UC patients than adultonset UC patients \[[@b55-ir-2018-00128]\]. From a meta-analysis of population-based studies, the pooled risk of colectomy at 1, 5, and 10 years after diagnosis was 7%, 17%, and 22%, respectively in pediatric-onset UC patients \[[@b56-ir-2018-00128]\]. Meanwhile, the pooled risk of colectomy was 5%, 12%, and 16%, respectively among all age groups of UC patients diagnosed after 1955 \[[@b56-ir-2018-00128]\]. The risk of colectomy at 5 years was significantly higher in pediatric populations (*P*=0.02) \[[@b56-ir-2018-00128]\].

Growth and pubertal maturity have a significant impact on decisions regarding treatment policy, particularly in children requiring optimal nutritional support, pharmacological treatment, and surgical treatment \[[@b54-ir-2018-00128]\]. Enteral nutrition helps to restore nutritional status, and anti-TNF agents can increase growth rate by inducing and maintaining remission in pediatric-onset CD patients \[[@b57-ir-2018-00128]\]. According to small cohort studies, infliximab has been reported to be helpful for restoring linear growth and weight gain as well as improving intestinal inflammation in pediatric CD patients, and clinical response to adalimumab has also been reported to be associated with linear growth \[[@b57-ir-2018-00128]-[@b59-ir-2018-00128]\]. Moreover, improvement in linear growth after infliximab administration could be independent of the progression of puberty and reduction of glucocorticoid dose \[[@b60-ir-2018-00128]\]. Monitoring growth and pubertal development is important for assessing the impacts of the disease itself and the response to treatment, particularly in pediatric-onset CD patients \[[@b39-ir-2018-00128]\].

WHAT IS THE TRANSITION OF CARE?
===============================

Transfer of care refers to the actual movement of patients and their medical records from one healthcare provider to another at a specific point in time \[[@b3-ir-2018-00128],[@b14-ir-2018-00128]\]. In contrast, the transition of care is a process rather than a single point in time, which is defined as "the purposeful and planned movement that addresses the medical, psychosocial and educational/vocational needs of adolescents and young adults with chronic physical and medical conditions as they move from child-centered to adult-oriented healthcare systems." \[[@b61-ir-2018-00128]-[@b63-ir-2018-00128]\] The optimal goal of the transition of care is to provide consistent, harmonious, developmentally appropriate, psychosocially sound, and comprehensive healthcare to patients with IBD \[[@b61-ir-2018-00128]\].

Successful transition can help normalize growth and development, promote independent behavior, improve compliance with therapy, provide an appropriate environment, and establish long-term plans \[[@b64-ir-2018-00128]\]. However, the failure of transition can lead to non-adherence to medical therapy, poor healthcare attendance, and the subsequent flare leading to deterioration of disease course, which is a major challenge for healthcare providers \[[@b65-ir-2018-00128],[@b66-ir-2018-00128]\]. Moreover, adolescence, the period when the transitioning process is usually initiated, is a crucial time of change in the lives of patients, when patterns of lifelong health behaviors are established \[[@b67-ir-2018-00128]\].

Transition encompasses both pediatric and adult care \[[@b68-ir-2018-00128]\]. Pediatric care differs from adult care in that it tends to be familycentered, and multidisciplinary practices therefore often require parental direction and consent \[[@b63-ir-2018-00128]\]. In contrast, adult care tends to be patient-centered and is mainly provided by a single doctor, and autonomous and independent patients are expected in an adult care setting \[[@b63-ir-2018-00128]\]. A transitioning patient may find it difficult to adapt to adult care, which focuses on cancer surveillance, sexual function, fertility, and pregnancy in contrast to the focus on growth and development in pediatric care \[[@b65-ir-2018-00128]\].

TRANSITION PROCESS
==================

The transition process can be started most sensibly when the patient is capable of abstract thinking and future orientation \[[@b63-ir-2018-00128]\]. This usually begins in the early adolescence of patients--at the age of 10 to 12 years--and the final transfer to adult care occurs most often between 18 and 23 years of age \[[@b14-ir-2018-00128]\]. However, this is a flexible rather than a rigid protocol that must be tailored to the patients' developmental abilities and situation \[[@b64-ir-2018-00128]\]. According to the position statements of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition published in 2002, pediatric care providers should initiate a transition process when the patients enters early to middle adolescence by meeting them without their parents, discussing the benefits of transition with the patient and family, developing relationships with competent adult care providers, and transferring all necessary medical information and summaries \[[@b64-ir-2018-00128]\].

Healthcare transition planning algorithms for children and youth with special healthcare needs were proposed in 2011 to assist healthcare providers in their execution of the transitional process and provide information about the transition structure for pediatric patients and their families \[[@b11-ir-2018-00128]\]. In this context, action steps developed according to a patient's specific age range are of particular importance \[[@b11-ir-2018-00128]\]. At 12 to 13 years of age, after the initiation of transition planning, a written transition policy that explicitly states the expectations associated with the care practices and processes should be shared with patients and their families \[[@b11-ir-2018-00128]\]. At 14 to 15 years of age, the patient's transition readiness is assessed, and a transition plan is jointly developed through patient and family interviews \[[@b11-ir-2018-00128]\]. Transition plans should be reviewed on a regular basis and updated as needed at 16 to 17 years of age. After preparing for adult care, the implementation of the adult care model occurs in patients aged 18 or over, who have already completed the previous steps \[[@b11-ir-2018-00128]\].

In general, the key competencies that should be gained during the transition process include knowledge about the medical condition and its treatment, self-efficacy, self-management, decision making, problem solving, self-advocacy, and information gathering \[[@b65-ir-2018-00128]\]. Self-management skills include medication adherence and the adequate management of symptoms, side effects of medication, stress, and emotion \[[@b69-ir-2018-00128],[@b70-ir-2018-00128]\]. However, in practice, a high proportion of adult and pediatric gastroenterologists reported inadequacies in the preparation of patients for transfer, and there was a significant difference in perceived inadequacies between adult and pediatric gastroenterologists (79% vs. 42%, *P*=0.001) \[[@b9-ir-2018-00128]\]. The acquisition of knowledge and self-management skills should proceed with a stepwise approach, and tasks for the patient and medical team according to the patients' chronological age have been proposed in the form of a checklist ([Fig. 1](#f1-ir-2018-00128){ref-type="fig"}) \[[@b63-ir-2018-00128]\]. Smartphone applications, such as GI buddy, myIBD+, and myColitis, can be helpful as tools to track the symptoms, diet, mood, and medication use of IBD patients and to improve their knowledge of IBD and self-management skills \[[@b71-ir-2018-00128]\].

Although there has been no universal instrument for measuring transition readiness, the Transition Readiness Assessment Questionnaire, the Social-ecological Model of Adolescents and Young Adults Readiness for Transition (SMART), the Readiness for Transition Questionnaire, and the University of North Carolina TRxANSITION scales were developed to evaluate the transition readiness for chronic health conditions \[[@b72-ir-2018-00128]-[@b76-ir-2018-00128]\]. For IBD patients, MyHealth Passport and the checklist by Fishman et al. were also developed \[[@b77-ir-2018-00128],[@b78-ir-2018-00128]\]. In addition, the IBD Self-efficacy Scale for Adolescents and Young Adults (IBDSES-A) and a questionnaire (IBD-yourself) for evaluating self-efficacy have been introduced \[[@b79-ir-2018-00128]-[@b81-ir-2018-00128]\]. Patients are considered eligible for adult care when most of the transition readiness skills have been mastered, the underlying disease is mild or quiescent, a patient has identified an adult care provider, and the pediatric care providers consider it likely that transition will be successful \[[@b13-ir-2018-00128]\].

[Fig. 2](#f2-ir-2018-00128){ref-type="fig"}. summarizes what we must consider and monitor during the different stages including before, just before, and during transition process \[[@b82-ir-2018-00128]\].

OBSTACLES TO SUCCESSFUL TRANSITION
==================================

Previous studies have reported that pediatric-onset IBD patients demonstrated deficits in important knowledge regarding their medical history and medication regimens and deficits in their self-management skills \[[@b8-ir-2018-00128],[@b70-ir-2018-00128]\]. In a cross-sectional assessment of knowledge among Canadian patients, less than 50% of pediatric patients responded correctly to questions about small bowel X-ray results (9%), their overall disease location (22%), health service resources such as insurance providers (30%) and pharmacy (35%), their previous surgery (31%), and the date, within 6 months, of their most recent colonoscopic evaluation (45%) \[[@b77-ir-2018-00128]\]. Compared with their parents, pediatric patients were less knowledgeable about the date of their last admission and health service resources, although other items were not significantly different between pediatric patients and their parents \[[@b77-ir-2018-00128]\]. A survey of adult gastroenterologists in the United States also reported that pediatric-onset IBD patients lacked knowledge of their medical history (55%) and medication regimen (69%), and moreover, 51% of doctors noted that they had received inadequate medical history from pediatric care providers \[[@b8-ir-2018-00128]\]. Therefore, tools that can be used as a portable medical record, such as the MyHealth Passport for IBD, can help reduce this knowledge gap \[[@b77-ir-2018-00128]\].

Self-management behaviors are influenced by sociodemographic factors, such as level of education and employment status; disease or disease regimen factors; individual factors; and family, social, and healthcare system factors \[[@b70-ir-2018-00128]\]. Approximately 38% to 66% of pediatric-onset IBD patients have shown medication non-adherence in previous reports, with variation depending on the respondents, the type of medication, and the method of evaluation \[[@b83-ir-2018-00128]-[@b87-ir-2018-00128]\]. Pediatric-onset IBD patients responded that barriers to adherence were lack of time (33%), feeling well (16%), adverse drug reactions (14%), the belief that the medication was not working (14%), pharmacy barriers (8%), and insurance barriers (5%) \[[@b83-ir-2018-00128]\].

According to a national survey of pediatric care providers in the United States, the most frequently mentioned barriers to successful transition were (in order of frequency) the reluctance of patients and parents, unpreparedness of patients, lack of resources/manpower, poor coordination of care between pediatric and adult care providers, the reluctance of the provider, and difficulty in finding an adult provider \[[@b12-ir-2018-00128]\]. The components of the SMART scale includes the following barriers to or facilitators of transition: preexisting objective factors; sociodemographic/culture, healthcare access/insurance, health status/risk, neurocognition/intelligent quotient, and interrelated subjective variables; knowledge, skills/efficacy, beliefs/expectations, goals, relationships, and psychosocial functioning \[[@b68-ir-2018-00128],[@b74-ir-2018-00128]\]. Those SMART components that addressed the patient's level of developmental maturity, the style of parental involvement, and the degree of support from providers were reported to influence transitional outcomes such as healthcare utilization, health status, and quality of life \[[@b88-ir-2018-00128]\].

According to a survey of adult and pediatric gastroenterologists in the United Kingdom, the main organizational obstacles include a lack of funding and support services; a lack of time, space, and training; and the small number of patients \[[@b9-ir-2018-00128]\]. The desired resources of United States pediatricians includes additional staff, reimbursement for transition-related services, and joint clinic visits with pediatric and adult providers \[[@b12-ir-2018-00128]\].

OUTCOMES OF TRANSITION
======================

During the transition from pediatric to adult care, there is a high risk of non-adherence to treatment. If done poorly, transition can affect not only the use of health services but also the patient's health \[[@b89-ir-2018-00128]\]. Although there have been few studies on patients with IBD, implementing an effective transition care program can help improve patients' medication adherence and their health and life outcomes while promoting self-reliance \[[@b89-ir-2018-00128],[@b90-ir-2018-00128]\].

In a study of IBD patients who had been transitioned to adult care in France, most patients (85%) stated that they felt ready for transition, and both patients and their parents' attend to a joint medical clinic with pediatric and adult gastroenterologists were considered beneficial for building patients' confidence in new providers and transmitting information \[[@b91-ir-2018-00128]\]. In a recent study conducted in Israel, pediatric-onset IBD patients attended a multidisciplinary transition clinic with a pediatric gastroenterologist, an adult gastroenterologist, an IBD nurse, a psychologist, and a nutritionist as needed, in 4 structured visits over a period of 6 months \[[@b80-ir-2018-00128]\]. The self-efficacy scores in all of the domains such as knowledge of IBD, treatment and transition process, self-efficacy in medication use, skills for independent outpatient clinic visits, actual behavior at the outpatient clinic, coping with IBD, and transfer readiness improved significantly after transition, and the level of improvement correlated to the number of meetings in the clinic \[[@b80-ir-2018-00128]\].

In a prospective study conducted in Canada, pediatric patients attending a transition clinic had stronger beliefs regarding the necessity for IBD drugs (*P*=0.004), were less skeptical (7% vs. 21%, *P*=0.03), and were more ambivalent (61% vs. 34%, *P*=0.004) in terms of their attitudes toward medicine than a control group, although self-reported adherence was not statistically different compared with controls \[[@b92-ir-2018-00128]\]. In a retrospective study conducted in the United Kingdom, patients who experienced a transition program showed a higher percentage of medication adherence (89% vs. 46%, *P*=0.002), a lower surgical rate (25% vs. 46%, *P*=0.01) or hospitalization rate (29% vs. 61%, *P*=0.002) within 2 years of transfer, and a lower rate of nonattendance at the clinic (29% vs. 78%, *P*=0.001) than those who did not \[[@b93-ir-2018-00128]\]. In this study, however, interpretation was limited because there were some differences in disease duration and medication history, although these were not significant \[[@b93-ir-2018-00128]\].

CONCLUSIONS
===========

Pediatric-onset IBD patient in the transition period stand at the crossroads between being an independent adult who has acquired knowledge and self-management skills and remaining a dependent child. Transition encompasses both pediatric and adult care, and the care providers who are responsible for transition should understand the difference between pediatric-onset and adult-onset IBD. Furthermore, to ensure successful transition, healthcare providers must have a precise understanding of the transition process, its obstacles, and its outcomes and should share this understanding with the patients and their families or other care providers.

**FINANCIAL SUPPORT**

The authors received no financial support for the research, authorship, and/or publication of this article.

**CONFLICT OF INTEREST**

BDY has received a research grant from Celltrion; consulting fees from Abbvie Korea, Ferring Korea, Janssen Korea, Kangstem Biotech, Kuhnil Pharm., Shire Korea, Takeda Korea, IQVIA, Cornerstones Health, and Robarts Clinical Trials Inc.; speaking fees from Abbvie Korea, Janssen Korea, Shire Korea, Takeda Korea, and IQVIA. However, all of these are not relevant to this article.

**AUTHOR CONTRIBUTION**

Conceptualization, writing, editing, and approval of the final manuscript: Ye BD. Conceptualization and writing: Kim J.

![Checklists of transition readiness according to chronological age. Checklist of tasks for the patient and the medical team based on chronological age. Adapted from Hait E, et al. Inflamm Bowel Dis 2006;12:70-73, with permission from Oxford University Press \[[@b63-ir-2018-00128]\].](ir-2018-00128f1){#f1-ir-2018-00128}

![What to consider and monitor in different stages of pediatric patients undergoing transition. A summary of the different stages of adolescents and young people (AYP) with IBD transition that highlights elements that must be monitored during this process from the perspective of pediatric to adult healthcare services. MDT, multidisciplinary team. Adapted from Brooks AJ, et al. Frontline Gastroenterol 2018;9:37-44, with permission from BMJ Publishing Group Ltd \[[@b82-ir-2018-00128]\].](ir-2018-00128f2){#f2-ir-2018-00128}

[^1]: These reviews are being published simultaneously in the *Intestinal Research* and *Pediatric Gastroenterology, Hepatology & Nutrition*.
